TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23143828

Group type: EXPERIMENTAL
Intervention: Psychometric assessment and feedback systems
Number of subjects: 400

Group type: COMPARATOR
Intervention: Peer review system based on qualitative individual case reports
Number of subjects: 400
Study: 20813792

Group type: EXPERIMENTAL
Intervention: Folic acid (exact dosage not specified)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 17999737

Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride (SnF(2))
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.2% sodium fluoride (NaF)
Number of subjects: 32
Study: 15890561

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX) 100 mg orally once daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX) 300 mg orally once daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 178
Study: 12190714

Group type: EXPERIMENTAL
Intervention: Provider support for self-management of bipolar disorder
Number of subjects: 420
Study: 9831969

Group type: EXPERIMENTAL
Intervention: 4 mg/kg loading dose of gentamicin or tobramycin (study group, n=4)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional dosing regimen of 2 mg/kg loading dose followed by maintenance dose (control group, n=7)
Number of subjects: 11
Study: 8092111

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin plus Amikacin (arm A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (arm B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 2530716

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular hepatitis B vaccination
Number of subjects: 0
Study: 31348243

Group type: EXPERIMENTAL
Intervention: Magnetostimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Magnetoledtherapy
Number of subjects: 30
Study: 28504307

Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention (FSI‐HIV)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 170
Study: 26363186

Group type: EXPERIMENTAL
Intervention: Coaching by speech-language pathologists (4 in-service workshops plus 5 individualized coaching sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (4 workshops only)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Coaching by speech-language pathologists
Number of subjects: 32
Study: 23368827

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (D + E)
Number of subjects: 14
Study: 21993710

Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg once daily)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 577
Study: 19624387

Group type: EXPERIMENTAL
Intervention: Quetiapine, 300-600 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16687036

Group type: EXPERIMENTAL
Intervention: MiniMizer Extra band
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical bands
Number of subjects: 60
Study: 14741082

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 g
Number of subjects: 120

Group type: COMPARATOR
Intervention: Aprotinin (AP) high-dose according to Hammersmith
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Aprotinin (AP)
Number of subjects: 120
Study: 11281506

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 71

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 71
Study: 9221454

Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 1374

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 1374
Study: 8038000

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3326574

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) mask
Number of subjects: 10

Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diary card evaluation during PEP mask therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diary card evaluation during postural drainage
Number of subjects: 10
Study: 29453419

Group type: EXPERIMENTAL
Intervention: Consent intervention using a lower literacy, less dense form
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard consent encounter
Number of subjects: 188
Study: 27507856

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 6756

Group type: COMPARATOR
Intervention: Placebo/Open Control
Number of subjects: 6756
Study: 24627301

Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Almorexant 1000 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zolpidem 40 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 22162575

Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin (GC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: methotrexate/carboplatin/vinblastine (M-CAVI)
Number of subjects: 238
Study: 21280424

Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice
Number of subjects: 100

Group type: COMPARATOR
Intervention: Negative control dentifrice (Crest Cavity Protection)
Number of subjects: 100
Study: 18798500

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 1.6 mg hypodermic injection, administered for 10 times
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Number of subjects: 80
Study: 16395874

Group type: EXPERIMENTAL
Intervention: Bangla translation of the Youth Self-Report (YSR) questionnaire
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Bangla version of the YSR
Number of subjects: 365
Study: 12775884

Group type: EXPERIMENTAL
Intervention: Central retinal artery (CRA) Doppler flowmetry
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control subjects (adjusted)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Number of small infarcts
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Grade of periventricular hyperintensities
Number of subjects: 103
Study: 10379630

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 195

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 195
Study: 8885956

Group type: EXPERIMENTAL
Intervention: t.i.d. dosing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: b.i.d. dosing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: t.i.d. and titration conditions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: b.i.d. and t.i.d. schedules
Number of subjects: 25
Study: 2063702

Group type: EXPERIMENTAL
Intervention: Calorie control, sodium restriction, potassium increases
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Baseline levels of urine sodium, urine potassium, and weight
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Household composition and control over food selection/preparation
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Number of complaints about diets
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Attendance at treatment sessions
Number of subjects: 841
Study: 6391932

Group type: EXPERIMENTAL
Intervention: diflunisal 1000 mg daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: naproxen 750 mg daily
Number of subjects: 47
Study: 30486711

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (guideline-directed therapy for HF)
Number of subjects: 132
Study: 27171812

Group type: EXPERIMENTAL
Intervention: Clinical Nursing Path (CNP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard nursing care (Control)
Number of subjects: 120
Study: 26355171

Group type: EXPERIMENTAL
Intervention: BB group (anorganic bovine bone (Bio‐Oss) and collagen porcine membranes (Bio‐Gide))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BB group
Number of subjects: 50

Group type: COMPARATOR
Intervention: CJ group (synthetic resorbable bone graft substitute made of pure β‐tricalcium phosphate (Ceros TCP) and porcine pericardium collagen membranes (Jason))
Number of subjects: 50
Study: 23453726

Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training (24 sessions over 8 weeks, 20 minutes walking per session)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-disabled group (comparison group)
Number of subjects: 19
Study: 21956960

Group type: EXPERIMENTAL
Intervention: α‐tocopherol (vitamin E)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: β‐carotene
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both α‐tocopherol and β‐carotene
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18829623

Group type: EXPERIMENTAL
Intervention: Cow's milk
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Soy
Number of subjects: 23
Study: 17196488

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 30 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 40 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline with bupivacaine 0.5% hyperbaric (control group)
Number of subjects: 60
Study: 16305005

Group type: EXPERIMENTAL
Intervention: Manual toothbrush and dental water jet (Group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush and dental water jet (Group 3)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Manual toothbrush and floss (Group 1)
Number of subjects: 105
Study: 12077088

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg intravenously three times a week for two weeks)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg intravenously three times a week for four weeks)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: ISIS 2302
Number of subjects: 299
Study: 10213349

Group type: EXPERIMENTAL
Intervention: Training group (n=12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 27
Study: 7593704

Group type: COMPARATOR
Intervention: Hibident (positive control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Parodex
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prexidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alodont
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eludril
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hextril
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hibident, Parodex, Prexidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eludril, Hextril
Number of subjects: 6
Study: 2229840

Group type: EXPERIMENTAL
Intervention: Salsalate (2 gm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 10
Study: 656251

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 30621460

Group type: EXPERIMENTAL
Intervention: Lifestyle-based pressure injury prevention program
Number of subjects: 25
Study: 31397702

Group type: EXPERIMENTAL
Intervention: Costoclavicular BPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supraclavicular BPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipsilateral hemidiaphragmatic paresis present
Number of subjects: 40
Study: 28237428

Group type: EXPERIMENTAL
Intervention: Adjunct slow-release dexamethasone implant (Ozurdex; 0.7 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Adjunct slow-release dexamethasone implant (Ozurdex)
Number of subjects: 140
Study: 25475363

Group type: EXPERIMENTAL
Intervention: 6-month social communication intervention including parent training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Observation of sessions
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active coaching and workshops
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Parents' implementation of strategies
Number of subjects: 61
Study: 24045678

Group type: EXPERIMENTAL
Intervention: Paroxetine 7.5 mg
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study: 21197524

Group type: EXPERIMENTAL
Intervention: MAL-PDT with blue light source
Number of subjects: 18

Group type: COMPARATOR
Intervention: MAL-PDT with red light source
Number of subjects: 18
Study: 19414940

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg after each dialysis session for six months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spironolactone and Placebo
Number of subjects: 16
Study: 17879663

Group type: EXPERIMENTAL
Intervention: Right nostril yoga breathing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alternate nostril yoga breathing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left nostril yoga breathing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breath awareness (control)
Number of subjects: 20
Study: 15486923

Group type: EXPERIMENTAL
Intervention: PTFE-covered stents
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 25
Study: 16519421

Group type: EXPERIMENTAL
Intervention: Modified motor cortex stimulation (MCS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pharmacological testing (phentolamine, lidocaine, ketamine, thiopental, morphine, placebo)
Number of subjects: 15
Study: 9848030

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 227
Study: 7848901

Group type: EXPERIMENTAL
Intervention: Guggulipid (50 mg capsules twice daily for 24 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (capsules twice daily for 24 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Guggulipid (after 12-week washout)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (after 12-week washout)
Number of subjects: 61
Study: 2903480

Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) 200 mg/kg
Number of subjects: 146
Study: 4513355

Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy as the only form of maintenance
Number of subjects: 72

Group type: COMPARATOR
Intervention: Weekly immunotherapy in addition to chemotherapy
Number of subjects: 72
Study: 27909712

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion SPECT (MPS) using Tc‐99m radiopharmaceuticals
Number of subjects: 121939

Group type: EXPERIMENTAL
Intervention: Pharmacological stress tests (adenosine, regadenoson, dipyridamole, dobutamine)
Number of subjects: 121939

Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 121939

Group type: EXPERIMENTAL
Intervention: MPS scoring by default
Number of subjects: 121939

Group type: EXPERIMENTAL
Intervention: Increase in MPS count
Number of subjects: 121939

Group type: EXPERIMENTAL
Intervention: Requests for MPS
Number of subjects: 121939
Study: 26365443

Group type: EXPERIMENTAL
Intervention: Oral administration of PTQXT
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Oral administration of PTQXT combined with external application of Chinese herbs
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (oral antihistamine and placebo PTQXT pills with topical 1% mometasone furoate)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Both Chinese herbal medicine-treated groups
Number of subjects: 275
Study: 23311981

Group type: EXPERIMENTAL
Intervention: Nurse telephone follow-up on postoperative days 1, 3, 5, and 10
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard care with no follow-up
Number of subjects: 45
Study: 22289539

Group type: COMPARATOR
Intervention: Ketamine 2 mg/kg intravenous bolus plus normal saline by intravenous infusion (K group, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg intravenous bolus plus remifentanil 0.15 μg/kg per min intravenous infusion (KR group, n = 30)
Number of subjects: 60
Study: 19491658

Group type: EXPERIMENTAL
Intervention: Intravenous ATP (8‐10 h/week, maximum 50 microg/kg/min) for 8 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: No ATP (control group)
Number of subjects: 99
Study: 16941969

Group type: EXPERIMENTAL
Intervention: Oral anti-inflammatory analgesic medicine combined with acupuncture at Tiaokou (ST 38)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Oral anti-inflammatory analgesic medicine
Number of subjects: 257
Study: 12694150

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 micro g kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10731509

Group type: EXPERIMENTAL
Intervention: High-calcium mineral water (344 mg Ca/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-calcium mineral water (<10 mg/L)
Number of subjects: 12
Study: 9163027

Group type: EXPERIMENTAL
Intervention: Aciclovir (treatment of choice for HSE)
Number of subjects: 0
Study: 1568701

Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Billroth II anastomosis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Roux-en-Y and Billroth II anastomosis
Number of subjects: 22
Study: 6146156

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31461079

Group type: EXPERIMENTAL
Intervention: Nurse-led multicomponent intervention
Number of subjects: 46
Study: 30596746

Group type: EXPERIMENTAL
Intervention: Trial SMS (N = 195)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Trial Control (N = 193)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Comparison Cohort (N = 727)
Number of subjects: 388
Study: 27372434

Group type: EXPERIMENTAL
Intervention: Lidocaine pre-administration (1% lidocaine 30mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Local warming (43°C forced air for 1min)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 24875302

Group type: EXPERIMENTAL
Intervention: Genome sequencing information
Number of subjects: 39
Study: 22689677

Group type: EXPERIMENTAL
Intervention: sirolimus/tacrolimus
Number of subjects: 74

Group type: COMPARATOR
Intervention: methotrexate/tacrolimus
Number of subjects: 74
Study: 20653641

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg daily for 3 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18983270

Group type: EXPERIMENTAL
Intervention: Oportunidades conditional cash transfer programme
Number of subjects: 840
Study: 11236121

Group type: EXPERIMENTAL
Intervention: Single dose systemic methotrexate (50 mg/m2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 62
Study: 10211031

Group type: EXPERIMENTAL
Intervention: 5% liposome-encapsulated tetracaine (LET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% eutectic mixture of local anaesthetics (EMLA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall anaesthetic effect
Number of subjects: 40
Study: 7877746

Group type: EXPERIMENTAL
Intervention: Medicated patients with Parkinson's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 0
Study: 3357154

Group type: EXPERIMENTAL
Intervention: Intermittent 'low-friction' self-catheterization
Number of subjects: 42

Group type: COMPARATOR
Intervention: Urethrotomy
Number of subjects: 42
Study: 31593081

Group type: EXPERIMENTAL
Intervention: Multicomponent therapy (MT group) consisting of health education, exercise, and cognitive-behavioral therapy during 12 weeks in 2-hourly weekly sessions.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual clinical care (control group).
Number of subjects: 336
Study: 28291838

Group type: EXPERIMENTAL
Intervention: Theoretical and practical exercise counseling
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 26116999

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 19
Study: 23076726

Group type: EXPERIMENTAL
Intervention: Building-only intervention
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 2500
Study: 21569242

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg on Day 1
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg on Day 8
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg (Days 1 to 7)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg (Days 8 to 36)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 39 mg (Days 8 to 36)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg (Days 8 to 36)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 19355800

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16573577

Group type: EXPERIMENTAL
Intervention: Alcohol plus energy drink (vodka 37.5% v/v and Red Bull 3.57 mL/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Energy drink alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 26